We demonstrated that these exhausted CD8+ T cells were in an aberrantly differentiated status, uniquely positioned and revealed as a useful biomarker to predicting unfavorable outcomes in two independent cohorts of HCC patients. This evidence concerns the gene CD8A and hepatocellular carcinoma.